Navigation Links
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO

MILWAUKEE, July 25, 2013 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a private, emerging pharmaceutical company focused on developing a therapeutic platform for neuropsychiatric disorders, with an initial emphasis on creating drugs for the treatment of schizophrenia, announced today that Chad Beyer, Ph.D., MBA, has been appointed as President and Chief Executive Officer.

With nearly 20 years experience, Dr. Beyer's career encompasses research, discovery and the business development of medications intended for central nervous system (CNS) and neurological disorders.  As an entrepreneur, Dr. Beyer has founded a biotech consulting company and helped launch a specialty pharmaceutical company focused on developing treatments for acute pain conditions.

Klaus Veltinger, M.D., Ph.D., and chairman of Promentis' board of directors, stated, "We are thrilled to have Chad on board, he brings exceptional development experience to a well-established program that has already made considerable progress."   

Given Dr. Beyer's significant and extremely relevant experience in neuroscience, we're confident his abilities will have a direct and marked impact on Promentis' growth efforts."

For more than a decade, Dr. Beyer worked in the Discovery Neuroscience group at Wyeth Pharmaceuticals, where he held multiple positions of increasing responsibility, including Head of Neurochemistry.  During his time at Wyeth, he also led several drug discovery teams and managed a group of scientists that contributed to the submission of more than 30 INDs and generated supporting data for the commercialization and life-cycle management of Effexor® and Pristiq®, two of the company's blockbuster medications.

"Promentis is aggressively moving innovative science and novel treatment strategies closer to the millions of people suffering with CNS diseases," said Dr. Beyer.  "I am honored to join this unique team and to lead the company's drug discovery efforts closer to patients and their families."

Shortly after beginning his research career at the National Institutes of Health (NIH) in NIDA's Addiction Research Center, Dr. Beyer earned his Ph.D. in Pharmacology from Louisiana State University Medical Center and an MBA from the Rutgers School of Business.  He has authored more than 70 manuscripts, been granted three patents, is an editor of Next Generation Antidepressants, a psychiatry review book, and is co-founder of the journal Technology Transfer & Entrepreneurship.  Dr. Beyer also serves as an adjunct faculty member at Thomas Jefferson University where he teaches Bioventure Management.

About Promentis Pharmaceuticals, Inc:
Promentis Pharmaceuticals, Inc. was founded in 2007 and is a private, emerging pharmaceutical company focused on developing unique compounds aimed at modifying brain chemistry for the treatment of schizophrenia and other central nervous system disorders.  Support for Promentis' drug discovery and development programs, in part, is provided by recent grants from the National Institute of Mental Health (NIMH) and the Michael J. Fox Foundation.  Additional information can be found at

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 375-2694
Andrew Mielach

SOURCE Promentis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Post Your Comments:
(Date:12/2/2015)... ) has ... Market by Product Type, Surgery Type, End ... 2020"  report to their offering.  --> ... of the  "Spine Biologics Market by Product ... - Global Forecast to 2020"  report to ...
(Date:12/2/2015)... , December 2, 2015 /PRNewswire/ ... announced the addition of the  "Global ... their offering.  --> ... the  "Global Laparotomy Sponge Market 2015-2019" ... Research and Markets ( ) ...
(Date:12/1/2015)... , Dec. 1, 2015 As enforcement ... Supply Chain Security Act (DSCSA) approaches, InfiniTrak ... and independent pharmacies comply with looming FDA regulations. ... InfiniTrak is entering endorsement agreements with State Pharmacy ... services administration organization (PSAO) to exclusively provide the ...
Breaking Medicine Technology:
(Date:12/2/2015)... Southlake, Texas (PRWEB) , ... December 02, 2015 ... ... S. Reeves, M.D., and Eric J. Coligado, M.D., are both included in the ... of the annual Super Doctors® list, employs a rigorous, multi-step process to select ...
(Date:12/2/2015)... ... December 02, 2015 , ... The International Association ... February 17 - 21 at the Omni on Amelia Island, Florida, featuring nationally ... FAED, CEDS, a clinical psychologist who has specialized in eating disorders and related ...
(Date:12/2/2015)... ... 2015 , ... First Choice Emergency Room , the largest network of ... the Medical Director of its new Round Rock facility. , “We are pleased ... Rock location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:12/2/2015)... ... 2015 , ... First Choice Emergency Room , the largest network of ... as the Medical Director of its new Frisco- Eldorado facility. , “We are ... Frisco- Eldorado location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:12/2/2015)... ... December 02, 2015 , ... Accreditation for Cardiovascular ... Washington area have completed the process of ACE accreditation for cardiac catheterization and ... St. Joseph Medical Center in Tacoma, St. Anthony Hospital in Gig Harbor, and ...
Breaking Medicine News(10 mins):